 DUBLIN, June 1, 2021 PRNewswire -- Alkermes plc Nasdaq: ALKS today announced that the U.S. Food and Drug Administration FDA has approved LYBALVITM olanzapine and samidorphan for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. LYBALVI is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity. 